EZH2 and diffuse large B-cell lymphoma: Given that the 5-year survival rate of GCB-DLBCL is ~59% with currently available immune chemotherapeutic agents, including R-CHOP, R-DHAP, R-ICE, and DA-EPOCH-R [41,42], targeting EZH2 to DLBCL with EZH2 mutations may be more beneficial.